Literature DB >> 15029260

Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.

Zahra Amirghofran1, Ahmad Monabati, Naser Gholijani.   

Abstract

The expression of several genes involved in the regulation of cell cycle and apoptosis may be regulated via the androgen receptor (AR) in the prostate. AR may have a role in the prognosis of prostatic carcinoma. The aim was to examine AR expression status and its relationship with markers of proliferation, apoptosis and cell cycle control in prostate cancer. Expression of AR, bcl-2, bax, Ki-67 and p53 was examined in paraffin-embedded tissues from 50 cases of prostate carcinoma by immunohistochemistry and evaluated using an index of staining. Detection of apoptotic cells was performed by TUNEL method. Correlation between AR expression and apoptosis, proliferation index, bcl-2, bax and p53 and also clinicopathological parameters including stage, pathological grade and Gleason score were determined. AR expression was observed in all cases with mean expression of 81%+/-15 and mean staining index of 141+/-65. No correlation was found between AR expression and apoptosis detected in patients. The mean AR staining index was 170+/-72 in bcl-2 positive tumors versus 120+/-53 in bcl-2 negative tumors showing a significant association between AR and bcl-2 expression (p=0.015). AR expression also showed a significant association with bcl-2/bax ratio (r=0.321, p=0.023) and Ki-67 proliferation staining index (r=0.396, p=0.004). Although a significant correlation between Ki-67 and p53 with differentiation status of the tumors was observed (p<0.004) no correlation was found with AR. AR expression showed no prognostic value regarding its correlation with stage and differentiation status of the prostate carcinoma. However, its significant correlation with Ki-67 and bcl-2 that are markers of cell survival suggest its contribution to tumor cell progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029260     DOI: 10.1007/BF02893407

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  [Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer].

Authors:  H Yoshikawa; T Ikeuchi; Y Kai
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1996-07

Review 2.  Multiple roles of the tumor suppressor p53.

Authors:  Jill Bargonetti; James J Manfredi
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

3.  Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids.

Authors: 
Journal:  Trends Endocrinol Metab       Date:  1999-03       Impact factor: 12.015

4.  Heterogeneity of androgen receptor content in advanced prostate cancer.

Authors:  C Magi-Galluzzi; X Xu; L Hlatky; P Hahnfeldt; I Kaplan; P Hsiao; C Chang; M Loda
Journal:  Mod Pathol       Date:  1997-08       Impact factor: 7.842

5.  Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue.

Authors:  K K Miyamoto; S A McSherry; G A Dent; M Sar; E M Wilson; F S French; Y Sharief; J L Mohler
Journal:  J Urol       Date:  1993-05       Impact factor: 7.450

Review 6.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Authors:  C Cadwell; G P Zambetti
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

Review 7.  Androgen receptors in prostate cancer.

Authors:  Zoran Culig; Helmut Klocker; Georg Bartsch; Hannes Steiner; Alfred Hobisch
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

8.  Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma.

Authors:  A G Aprikian; A S Sarkis; W R Fair; Z F Zhang; Z Fuks; C Cordon-Cardo
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

Review 9.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

10.  Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.

Authors:  G B Baretton; U Klenk; J Diebold; N Schmeller; U Löhrs
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  6 in total

Review 1.  Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.

Authors:  David Karnak; Liang Xu
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

2.  Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis.

Authors:  Behnaz Valibeigi; Zahra Amirghofran; Hossein Golmoghaddam; Reza Hajihosseini; Fatemeh M Kamazani
Journal:  Pathol Oncol Res       Date:  2013-11-12       Impact factor: 3.201

3.  Androgen Receptor Promotes Gastric Carcinogenesis via Upregulating Cell Cycle-Related Kinase Expression.

Authors:  Ren Wang; Xiao-Yi Xu; Hong Zhu; Xiong Liang; Xue Li; Ming-Xu Jia; Qing-Hua Wang; Hui-Yun Wang; Xiao-Xing Li; Gui-Jun Zhao
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

4.  Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.

Authors:  Ana Caroline Hillebrand; Lolita Schneider Pizzolato; Brasil Silva Neto; Gisele Branchini; Ilma Simoni Brum
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

5.  Tumor Cell Death via Apoptosis and Improvement of Activated Lymphocyte Cytokine Secretion by Extracts from Euphorbia Hebecarpa and Euphorbia Petiolata.

Authors:  Zahra Amirghofran; Narjes Shekofteh; Mehri Ghafourian; Neda Khosravi; Kurosh Kalantar; Saeed Malek-Hosseini
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01

6.  DiME: a scalable disease module identification algorithm with application to glioma progression.

Authors:  Yunpeng Liu; Daniel A Tennant; Zexuan Zhu; John K Heath; Xin Yao; Shan He
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.